专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060127502A1 Methods for inhibiting Stat3 signaling in immune cells 有权
标题翻译：抑制免疫细胞Stat3信号传导的方法
公开(公告)号：US20060127502A1
公开(公告)日：2006-06-15
申请号：US11300619
申请日：2005-12-14
申请人： Hua Yu , Richard Jove , Marcin Kortylewski , Drew Pardoll
发明人： Hua Yu , Richard Jove , Marcin Kortylewski , Drew Pardoll
IPC分类号： A61K48/00 , A61K33/24 , A61K31/28 , A61K31/7072 , A61K31/7076
CPC分类号： A61K31/28 , A61K31/7072 , A61K31/7076 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Methods of enhancing antitumor activity of an immune cell comprising contacting the immune cell with a Stat3 inhibitor are described. Also described are methods of killing a tumor cell or inhibiting tumor growth in a subject comprising contacting an immune cell of the subject with a Stat3 inhibitor.
摘要翻译：描述了增强免疫细胞的抗肿瘤活性的方法，包括使免疫细胞与Stat3抑制剂接触。还描述了杀死肿瘤细胞或抑制受试者肿瘤生长的方法，包括使受试者的免疫细胞与Stat3抑制剂接触。

2. 发明申请

US20090227489A1 STAT3 Agonists and Antagonists and Therapeutic Uses Thereof 审中-公开
标题翻译： STAT3激动剂及其拮抗剂及其治疗用途
公开(公告)号：US20090227489A1
公开(公告)日：2009-09-10
申请号：US12420704
申请日：2009-04-08
申请人： Hua Yu , Drew Pardoll , Richard Jove , William Dalton
发明人： Hua Yu , Drew Pardoll , Richard Jove , William Dalton
IPC分类号： A61K38/02 , A61K31/7105 , A61K31/711
CPC分类号： C12N5/0693 , A61K38/1709 , A61K38/204 , A61K48/005 , C12N2501/60 , C12N2510/00
摘要： The present invention relates to methods for modulating, i.e., agonizing or antagonizing, Stat3 (Signal Transducer and Activator of Transcription3) signaling activity for use in gene therapy. Inhibition and/or activation of Stat3 signaling is an effective approach to modulate angiogenesis and the immune response for treatment and/or prevention of inflammation, infection, inflammation, immune disorders, and ischemia.
摘要翻译：本发明涉及调节，即激动或拮抗Stat3（Transcription3的信号转导和激活因子）用于基因治疗的信号传导活性的方法。 Stat3信号传导的抑制和/或激活是调节血管生成和用于治疗和/或预防炎症，感染，炎症，免疫疾病和缺血的免疫应答的有效方法。

3. 发明申请

US20100297061A1 STAT3 ANTAGONISTS AND THEIR USES AS VACCINES AGAINST CANCER 审中-公开
标题翻译： STAT3拮抗剂及其作为疫苗的疫苗使用
公开(公告)号：US20100297061A1
公开(公告)日：2010-11-25
申请号：US12611732
申请日：2009-11-03
申请人： Hua Yu , Drew Pardoll , Richard Jove
发明人： Hua Yu , Drew Pardoll , Richard Jove
IPC分类号： A61K38/19 , A61P35/00 , A61K39/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/02 , A61P33/10
CPC分类号： C07K16/18 , A61K39/0011 , A61K48/00 , A61K2039/5152 , A61K2039/5154 , A61K2039/55522 , C12N5/0693 , C12N2501/60
摘要： The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcirption3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activation T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation.
摘要翻译：本发明涉及治疗和/或预防癌症的方法。特别地，本发明涉及离体免疫治疗方法。所述方法包括降低肿瘤细胞中Stat3（信号转导和转录激活因子3）的表达和/或功能，并将此类细胞施用于需要治疗和/或预防的受试者。本发明的其它方法包括通过与具有降低的Stat3表达或功能的肿瘤细胞共培养T细胞来活化T细胞。本发明还包括降低Stat3在抗原呈递细胞中的表达或功能的降低，并且向患者共同施用具有降低的Stat3功能的肿瘤细胞和抗原呈递细胞。本发明还涉及刺激树突状细胞分化的方法。

4. 发明授权

US07638122B2 Stat3 antagonists and their use as vaccines against cancer 有权
标题翻译： Stat3拮抗剂及其作为疫苗的用途
公开(公告)号：US07638122B2
公开(公告)日：2009-12-29
申请号：US10383707
申请日：2003-03-07
申请人： Hua Yu , Drew Pardoll , Richard Jove
发明人： Hua Yu , Drew Pardoll , Richard Jove
IPC分类号： A61K35/12 , A61K35/14 , A61K41/00
CPC分类号： C07K16/18 , A61K39/0011 , A61K48/00 , A61K2039/5152 , A61K2039/5154 , A61K2039/55522 , C12N5/0693 , C12N2501/60
摘要： The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcription3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activating T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation.
摘要翻译：本发明涉及治疗和/或预防癌症的方法。特别地，本发明涉及离体免疫治疗方法。所述方法包括降低Stat3（信号转导和转录激活因子3）在肿瘤细胞中的表达和/或功能，并将此类细胞施用于需要治疗和/或预防的受试者。本发明的其它方法包括通过与具有降低的Stat3表达或功能的肿瘤细胞共培养T细胞活化T细胞。本发明还包括降低Stat3在抗原呈递细胞中的表达或功能的降低，并且向患者共同施用具有降低的Stat3功能的肿瘤细胞和抗原呈递细胞。本发明还涉及刺激树突状细胞分化的方法。

5. 发明申请

US20070072822A1 STAT3 agonists and antagonists and therapeutic uses thereof 审中-公开
标题翻译： STAT3激动剂和拮抗剂及其治疗用途
公开(公告)号：US20070072822A1
公开(公告)日：2007-03-29
申请号：US11526367
申请日：2006-09-25
申请人： Hua Yu , Drew Pardoll , Richard Jove , William Dalton
发明人： Hua Yu , Drew Pardoll , Richard Jove , William Dalton
IPC分类号： A61K48/00 , A61K38/20 , A61K39/395
CPC分类号： C12N5/0693 , A61K38/1709 , A61K38/204 , A61K48/005 , C12N2501/60 , C12N2510/00
摘要： The present invention relates to methods for modulating, i.e., agonizing or antagonizing, Stat3 (Signal Transducer and Activator of Transcription3) signaling activity for use in gene therapy. Inhibition and/or activation of Stat3 signaling is an effective approach to modulate angiogenesis and the immune response for treatment and/or prevention of inflammation, infection, inflammation, immune disorders, and ischemia.
摘要翻译：本发明涉及用于调节，即激动或拮抗Stat3（信号传感器和转录3）用于基因治疗的信号传导活动。 Stat3信号传导的抑制和/或激活是调节血管生成和用于治疗和/或预防炎症，感染，炎症，免疫疾病和缺血的免疫应答的有效方法。

6. 发明申请

US20110195509A1 TREATMENT OF TH17-MEDIATED AUTOIMMUNE DISEASE VIA INHIBITION OF STAT 3 审中-公开
标题翻译：通过STAT3的抑制治疗TH17介导的自发性疾病
公开(公告)号：US20110195509A1
公开(公告)日：2011-08-11
申请号：US12677094
申请日：2008-09-05
申请人： Drew Pardoll , Charles Drake , Timothy Harris , Hua Yu
发明人： Drew Pardoll , Charles Drake , Timothy Harris , Hua Yu
IPC分类号： G01N33/68 , C07H21/02 , C07K16/18 , C07K16/24 , G01N33/48
CPC分类号： C07K16/2866 , A61K2039/507 , C07K16/244 , G01N33/564 , G01N33/6872 , G01N2800/12 , G01N2800/24 , G01N2800/26 , Y10T436/143333
摘要： Methods for treating autoimmune disease using one or more inhibitor of STAT3 are provided herein. Also disclosed are methods for diagnosing and monitoring autoimmune disease or the propensity to develop autoimmune disease in a subject. The present invention demonstrates that inhibition of STAT3 prevents development of autoimmune disease in vivo. Based on this finding, Stat3 inhibitors can be used to treat and/or diagnose autoimmune disease in a subject.
摘要翻译：本文提供了使用一种或多种STAT3抑制剂治疗自身免疫疾病的方法。还公开了用于诊断和监测自身免疫疾病或在受试者中发展自身免疫疾病的倾向的方法。本发明表明STAT3的抑制可预防体内自身免疫疾病的发展。基于这一发现，Stat3抑制剂可用于治疗和/或诊断受试者中的自身免疫性疾病。

7. 发明申请

US20090304711A1 Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies 审中-公开
标题翻译：用抗B7-H1抗体组合治疗癌症和传染病
公开(公告)号：US20090304711A1
公开(公告)日：2009-12-10
申请号：US12441996
申请日：2007-09-20
申请人： Drew Pardoll , Lieping Chen , Charles Drake , Andrea Cox
发明人： Drew Pardoll , Lieping Chen , Charles Drake , Andrea Cox
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2827 , A61K39/0011 , A61K39/39 , A61K39/39541 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/55516 , A61K2039/55522 , C07K16/2818 , C07K2317/76 , A61K2300/00
摘要： Described are uses of an agent that reduces B7-H1 interaction with PD-1, and particularly monoclonal antibodies that bind to B7-H1 and interfere with B7-H1 interaction with PD-1 in combination with a vaccine to provide synergistic effects. The application provides methods of treatment and vaccination based on the combination of these compounds on T cell responses.
摘要翻译：描述了减少与PD-1的B7-H1相互作用的试剂的用途，特别是结合B7-H1并干扰与PD-1与疫苗组合以提供协同效应的B7-H1相互作用的单克隆抗体。该应用提供了基于这些化合物对T细胞应答的组合的治疗和疫苗接种的方法。

8. 发明申请

US20100040636A1 Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists 审中-公开
标题翻译：通过使用抗体，激动剂和拮抗剂靶向神经元基因来操纵调节性T细胞和Dc功能
公开(公告)号：US20100040636A1
公开(公告)日：2010-02-18
申请号：US11991693
申请日：2006-09-11
申请人： Hong Yu , Drew Pardoll , Xiaoya Pan , Charles George Drake , Jonathan D. Powell , Ching-Tai Huang
发明人： Hong Yu , Drew Pardoll , Xiaoya Pan , Charles George Drake , Jonathan D. Powell , Ching-Tai Huang
IPC分类号： A61K39/395 , A61K35/12 , A61K38/16 , C07K16/00 , A61P31/00 , C07H21/00 , A61P35/00 , C12N15/63 , A61P37/06 , A01K67/027 , C12Q1/02
CPC分类号： C07K14/475 , A01K67/0275 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0325 , A61K38/00 , A61K48/00 , C07K16/22 , C07K2319/30 , C12N15/8509 , C12N2510/00 , C12N2830/008 , G01N33/505
摘要： We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.
摘要翻译：我们在这里证明神经细胞以抗原依赖的方式控制调节性T细胞的体内平衡。基于这一发现，我们在这里描述了神经元作为治疗剂在各种疾病设置中操作抗原特异性调节性T细胞的应用。因此，通过神经氨酸处理Treg细胞和DC可用于增强自身免疫性疾病，癌症和感染性疾病的免疫治疗，以及在供体淋巴细胞输注，骨髓移植以及其他类型的移植环境中增强淋巴细胞移植，以及收养转让。

9. 发明授权

US06268411B1 Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses 有权
标题翻译：使用多价嵌合肽加载的MHC / ig分子检测，激活或抑制抗原特异性T细胞依赖性免疫应答
公开(公告)号：US06268411B1
公开(公告)日：2001-07-31
申请号：US09150622
申请日：1998-09-10
申请人： Jonathan Schneck , Drew Pardoll , Sean O'Herrin , Jill Slansky , Tim Greten
发明人： Jonathan Schneck , Drew Pardoll , Sean O'Herrin , Jill Slansky , Tim Greten
IPC分类号： C07K16100
CPC分类号： A61K39/385 , A61K38/00 , A61K39/00 , A61K47/6425 , A61K47/6811 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , A61K2039/605 , A61K2039/6056 , C07K14/005 , C07K14/7051 , C07K14/70539 , C07K2319/00 , C07K2319/30 , C12N2710/14143 , C12N2740/13022 , C12N2740/14022 , C12N2760/16122 , C12N2760/16134
摘要： To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors. pepMHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These pepMHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and have uses as specific regulators of immune responses.
摘要翻译：为了增加肽/ MHC分子的可溶性类似物对其同源配体的有效亲和力，构建了二价肽/ MHC复合物。使用重组DNA策略，将编码MHC I类的DNA连接到编码鼠Ig重链的DNA上。利用MHC / Ig复合物均匀加载感兴趣的肽。流式细胞仪的结果表明，具有高亲和力的pepMHC / Ig复合物特异性结合携带其同源受体pepMHC / Ig复合物的细胞也可用于调节抗原特异性T细胞的效应子功能。这些pepMHC / Ig复合物可用于研究TCR / MHC相互作用和淋巴细胞跟踪，并将其用作免疫应答的特异性调节物。

10. 发明授权

US5637483A Irradiated tumor cell vaccine engineered to express GM-CSF 失效
标题翻译：辐射肿瘤细胞疫苗工程化以表达GM-CSF
公开(公告)号：US5637483A
公开(公告)日：1997-06-10
申请号：US265554
申请日：1994-06-23
申请人： Glenn Dranoff , Richard C. Mulligan , Drew Pardoll
发明人： Glenn Dranoff , Richard C. Mulligan , Drew Pardoll
IPC分类号： A61K39/00 , A61K39/21 , A61K48/00 , C12N15/00
CPC分类号： A61K39/21 , A61K39/0011 , A61K39/12 , A61K2039/5152 , A61K2039/5156 , A61K2039/55522 , A61K48/00 , C12N2740/13043
摘要： A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.
摘要翻译：通过共同施用细胞因子粘附或辅助分子和靶抗原来改变个体对靶抗原的特异性全身免疫应答的方法。靶抗原可以是肿瘤细胞，肿瘤细胞抗原，感染因子或其它外来抗原，或其它需要增强的全身免疫应答的抗原。或者，当需要抑制全身免疫应答时，抗原可以是非外源抗原。所产生的全身免疫应答对靶抗原是特异性的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式